Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Biodexa Pharmaceuticals ( (BDRX) ).
Biodexa Pharmaceuticals announced the appointment of Dr. Gary A. Shangold as Chief Medical Officer on January 22, 2025. This strategic hire comes as the company advances towards a global Phase 3 study for its FAP treatment. Dr. Shangold brings extensive experience from previous roles in drug development, which is expected to bolster Biodexa’s clinical expertise and operational execution. His appointment reflects the company’s commitment to strengthening its management team as it progresses in developing treatments for diseases with significant unmet needs.
More about Biodexa Pharmaceuticals
Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative treatments for diseases with unmet medical needs. The company’s lead development programs include eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare brain cancers. Biodexa utilizes proprietary drug delivery technologies to enhance the bio-delivery and bio-distribution of medicines, operating from its headquarters in Cardiff, UK.
YTD Price Performance: 7.58%
Average Trading Volume: 149,133
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.56M
Find detailed analytics on BDRX stock on TipRanks’ Stock Analysis page.
